Introduction
============

Increasing evidence has indicated that ozone therapy is effective for treating numerous types of diseases featuring chronic pain, including osteoarthritis ([@b1-etm-0-0-9005]), neck and shoulder pain ([@b5-etm-0-0-9005]), lower back pain ([@b6-etm-0-0-9005]), myofascial pain syndrome ([@b10-etm-0-0-9005]), fibromyalgia ([@b11-etm-0-0-9005]), complex regional pain syndrome ([@b12-etm-0-0-9005]), zoster-associated pain ([@b13-etm-0-0-9005],[@b14-etm-0-0-9005]) and other diseases, such as intractable headache and cardiovascular diseases ([@b15-etm-0-0-9005],[@b16-etm-0-0-9005]). Medical ozone is administered in a flexible manner and may be applied externally or orally. It may also be administered locally or intravenously. Ozonated autohemotherapy (OAH) is widely used in the treatment of chronic pain ([@b14-etm-0-0-9005],[@b16-etm-0-0-9005],[@b17-etm-0-0-9005]). It has been reported that OAH alleviated pain of patients with post-herpetic neuralgia ([@b14-etm-0-0-9005]), intractable headache ([@b16-etm-0-0-9005]), as well as hyperuricemia and gout ([@b17-etm-0-0-9005]). Moderate concentrations of ozone (10 or 50 µg/ml) have been reported to increase deformability of red blood cells ([@b18-etm-0-0-9005]) and OAH is able to ameliorate renal ischemia-reperfusion injury in patients with kidney injury ([@b19-etm-0-0-9005]).

The specific mechanisms of action of ozone treatment in various diseases remain to be further studied. It is thought that the effects of ozone treatment are based on its strong oxidative and anti-pathogenic effects and immune regulation ability, as well as the increase of oxygen supply and reduction of oxidative stress ([@b12-etm-0-0-9005],[@b20-etm-0-0-9005]). For instance, ozone was proven to relieve pain by causing the following effects: i) Release of endorphins ([@b26-etm-0-0-9005]); ii) inhibition of the activation of microglia via adenosine monophosphate (AMP)-dependent protein kinase signaling ([@b28-etm-0-0-9005]); iii) inhibition of the expression of purinergic receptors P2X3 and P2X7 in the spinal dorsal horn ([@b29-etm-0-0-9005]); iv) promoting phosphodiesterase 2A-cyclic guanosine monophosphate/cyclic AMP/NFκB-p65 signaling ([@b30-etm-0-0-9005]); v) inhibition of autophagy ([@b31-etm-0-0-9005],[@b32-etm-0-0-9005]); vi) reduction of the expression of pro-inflammatory/pro-apoptotic caspases ([@b33-etm-0-0-9005]); and vii) increase of oxygen supply in tissues and cells ([@b22-etm-0-0-9005]).

OAH comprises the drawing of blood and blood transfusion through a steel needle, which causes vascular damage. To prevent infection, the blood transfusion operation requires strict aseptic conditions in the operating room. Furthermore, OAH is time-consuming and cumbersome. Therefore, clinicians are exploring novel techniques for systemic ozone delivery. It has been proposed that ozonated saline infusion may be able to replace OAH. Compared to OAH, ozonized saline infusion is easy to perform and does not require the drawing of blood or blood transfusions. Furthermore, the requirements for the operating room are easy to fulfill and the cost is relatively low, making ozonated saline infusion a possible alternative to OAH therapy. Compared to the OAH, the ozonated saline is more convenient and more operable, however there is controversial about clinical application of ozonated saline. A comparison of the two types of infusion is presented in [Table I](#tI-etm-0-0-9005){ref-type="table"}.

Intravenous infusion of ozonated saline has been used in the clinic to treat a variety of diseases. A clinical study suggested that intravenous infusion of ozonated saline contributes to the elimination of macrophages from wounds, mainly through regulating genetically programed cell death (apoptosis), which has a significant role in the inflammatory process ([@b34-etm-0-0-9005]). Intravenous infusion of ozonated saline may improve symptoms of ischemia and hypoxia in the lower limbs of patients with occlusive atherosclerosis by stabilizing lysosomal hydrolase activity ([@b35-etm-0-0-9005]). Intravenous infusion of ozonized saline may also reduce the viscosity of blood and the aggregation of red blood cells, as well as enhance the deformability of red blood cells ([@b36-etm-0-0-9005]).

Animal studies have indicated that intravenous injection of 5 ml/kg ozonized saline bubbled with 4 µg/ml ozone in dogs increased the number of polymorphonuclear neutrophilic leukocytes, as well as their ability to capture bacteria for 2 days. In addition, this treatment led to an increase in the adaptability and compensatory capacity of the body ([@b37-etm-0-0-9005]). Intravenous infusion of ozonated saline may relieve liver injury induced by CCl~4~ via its effects on reactive oxygen species (ROS) and the Kelch-like ECH-associated protein 1/nuclear factor, erythroid 2-like 2/ARE signaling pathway in rats ([@b38-etm-0-0-9005]).

With the development of ozonated saline infusion, it has been suggested that ozonated saline may contain toxic substances, including hypochlorite, chlorite, chlorate or even perchlorate ([@b39-etm-0-0-9005]). However, it was reported that ozone interacts neither with Na^+^ nor with Cl^-^ and no sodium hypochlorite or other chlorine-containing oxygen ions were detected ([@b40-etm-0-0-9005]). The possible reaction mechanisms include the following: i) Chloride ions in normal saline are first oxidized by ozone to form chlorine atoms, initiating a chain reaction. The chlorine atoms are then oxidized by ozone to form harmful substances including chlorite, chlorate and perchlorate; ii) chloride ions are directly oxidized by ozone to form hypochlorite and oxygen, and hypochlorite is then oxidized by ozone to form chlorite, chlorate and perchlorate ([@b39-etm-0-0-9005]). These suggestions bring the clinical safety of ozonated saline infusion therapy into question ([@b41-etm-0-0-9005]).

In the present study, the safety of ozonated saline that may be used for intravenous infusion therapy was investigated. Ion chromatography-mass spectrometry (IC-MS) was used to determine the presence and content of chlorite, chlorate and perchlorate in ozonated saline at various time-points following preparation.

Materials and methods
=====================

### Materials

The following products were used in the present study: Medical ozone generator (Medozon compact, Herrmann Apparatebau GmbH); Dionex ICS5000^+^ ion chromatograph with EGC eluent autogenerator (Thermo Fisher Scientific, Inc.); AB 4000 QTRAP triple-quadrupole mass spectrometry system with electrospray ion source and Analyst 1.6.2 workstation (AB Sciex API 4000 Qtrap; AB Sciex LLC); Dionex Ion Pac AS16 anion analysis column (Thermo Fisher Scientific, Inc.); C18 solid-phase extraction (SPE) column (Agela Technologies); ozone-resistant blood bag (S-200; Sichuan Nigale Biomedical Co., Ltd.); bottled saline (Sichuan Kelun Pharmaceutical Co., Ltd.); and ozone-resistant syringe (Shenli).

### Preparation of ozonated saline

Ozone was produced with a medical ozone generator and various groups were set up. Ozone concentrations were set as 0 (100% oxygen), 20, 40 and 60 µg/ml in oxygen. Ozone and saline were mixed at a volume ratio of 1:1. Using a 50-ml anti-oxidation syringe ([Fig. 1A](#f1-etm-0-0-9005){ref-type="fig"}), 100 ml ozone of varying concentrations in oxygen, and 100 ml saline were drawn and mixed in saline bottles ([Fig. 1B](#f1-etm-0-0-9005){ref-type="fig"}) or ozone-resistant blood transfusion bags ([Fig. 1C](#f1-etm-0-0-9005){ref-type="fig"}). Ozonated saline was prepared and stored in room temperature without protection from light. On the 3rd, 6 and 15th day after the preparation, chlorite, chlorate and perchlorate in the ozonated saline were detected. The saline bottles and the blood bags had all been produced with the same batch numbers (E218092707 and 180808, respectively).

### Confirmation of chromatographic conditions

A Dionex ICS5000^+^ ion chromatograph system (Thermo Fisher Scientific, Inc.) was used. The mobile phase was KOH, the flow rate was set to 0.25 ml/min and the separation was performed on a Dionex Ion Pac AS16 analysis column (250x2 mm; Thermo Fisher Scientific, Inc.), and attached a Dionex Ion Pac AS16 anion guard column (50x2 mm; Thermo Fisher Scientific, Inc.). The column temperature was maintained at 25˚C during the operation. The injection volume was 25 µl. A 2-mm ASRS 500 anion suppressor (Thermo Fisher Scientific, Inc.) was used with an external water mode.

### Confirmation of mass spectrometry conditions

An AB 4000 Qtrap triple-quadrupole mass spectrometer was used for mass spectrometry. The ion source was set as electrospray negative ion mode. The source temperature was 500˚C. Further parameters were as follows: Ion spray voltage, -4,500 V; sprayer 1 (GS1), 206.84 kPa; GS2, 344.74 kPa. The transitions were used in multiple-reaction monitoring (MRM) mode. The collision gas was set to the medium mode. The surface heating system was set to open and the scan time was 200 msec.

### Selection of column and elution gradient

The Dionex Ion Pac AS16 anion analysis column (250x2 mm) and the corresponding guard column may rapidly and accurately detect trace amounts of perchlorate and other highly excited anions in multiple aqueous samples ([@b42-etm-0-0-9005]), and were therefore selected for the present study. In this experiment, 3, 25 and 45 mmol/l mobile phase (KOH) were used to analyze the separation effect of chlorite, chlorate and perchlorate.

### Optimization of mass spectrometry

A total of 5 ml of 1 mg/l chlorite, chlorate and perchlorate standard solution were prepared and a needle pump was used to continuously inject at a flow rate of 10 µg/min. First, a primary precursor ion scan (Q1MS mode) was performed. Under the selected mass spectrometry conditions, chlorite, chlorate and perchlorate demonstrated a good response. After the precursor ion was determined, the solution was subjected to a two-stage scan (Q1MI mode). The product ions with the highest response value were selected separately. The declustering potential (DP) value was optimized, and a three-stage mass spectrometry fragment scan (MS2 mode) was then performed, and the collision energy (CE) value was optimized. Finally, the solution was analyzed in MRM mode. Detected ion pairs and optimized DP and CE voltage values for chlorite, chlorate and perchlorate are presented in [Table II](#tII-etm-0-0-9005){ref-type="table"}.

### Confirmation of linear association, detection limit and quantitation limit

A total of five standard solutions (developed by the Ministry of Agriculture Environmental Protection Research Institute, Tianjin, China) with various concentrations (1, 2, 5, 10 and 20 µg/l) were accurately prepared and measured under optimized IC-MS conditions, as described above. Linear regression calculations were performed using the peak area (y-axis) of the analytes and the corresponding mass concentration (x-axis, µg/l) to obtain a linear regression equation and a linear correlation coefficient (R). This was used to determine the detection limit of an ion chromatographic peak at a signal-to-noise ratio (S/N)=3 and quantitation limit of peak at S/N=10. The results indicated that chlorite, chlorate and perchlorate had a good linear correlation in the corresponding mass concentration range and the linear correlation coefficient was \>0.999. The detection limits of chlorite, chlorate and perchlorate were 0.2, 0.5, and 0.01 µg/l, respectively. The quantitation limits of chlorite, chlorate and perchlorate were 0.7, 1.5 and 0.05 µg/l, respectively.

### Evaluation of precision and recovery rate

Samples were accurately weighed using 1, 2, 5, 10 and 20 µg/l of single standard solution and spiked recovery and precision tests were performed. The average recovery of each analyte was between 83.5 and 106.2%, and the relative standard deviation (n=6) was between 3.7 and 5.8%.

### Sample detection

The chloride ions in the sample solution were removed using a C18 SPE column at a flow rate of 3 ml/min and the concentrations of chlorite, chlorate and perchlorate in the sample were then measured using the method described above.

### Statistical analysis

Statistical analysis was performed using Prism (v.7.0; GraphPad Software, Inc.) or SPSS 19.0 (IBM Corp.). Values are expressed as the mean ± standard deviation. Statistical analysis between the groups of varying concentrations or containers was performed using repeated-measures two-way analysis of variance (ANOVA) tests followed by Sidak\'s multiple-comparisons tests. Statistical analysis of differences within the same concentration group at different time-points were performed using repeated-measures two-way ANOVA followed by Tukey\'s multiple-comparisons tests. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Chlorite, chlorate and perchlorate presented a good separation effect

Dionex Ion Pac AS16 anion analysis columns (250x2 mm) demonstrated a good separation effect on the chlorite, chlorate and perchlorate. An improved separation of chlorite, chlorate and perchlorate was achieved at the low mobile-phase concentration of 3 mmol/l KOH under the experimental conditions. The retention time of 7.2 min corresponded to chlorite, 13.5 min corresponded to chlorate and 20.8 min corresponded to perchlorate ([Fig. 1D](#f1-etm-0-0-9005){ref-type="fig"}).

### Chlorite was not detected in the ozone-saline or oxygen-saline solution

A total of five standard solutions (developed by the Ministry of Agriculture Environmental Protection Research Institute, Tianjin, China) with different concentrations (1, 2, 5, 10 and 20 µg/l) were added from low to high concentration for the spiked recovery test. Recovery rates on the 3rd day were 96.0-105.4%, those on the 6th day were 88.5-103.5% and those on the 15th day were 84.0-102.6%. The mass spectrometry results indicated that chlorite was not detected on the 3rd, 6 and 15th day in either the ozone-saline or oxygen-saline solutions.

### Chlorate was detected in the ozone-saline subgroups at the three time-points

The five standard solutions with different concentrations (1, 2, 5, 10 and 20 µg/l) were added from low to high concentration for the spiked recovery test. The recovery rates on the 3rd day were 88.5-106.0% and those on the 6th day were 83.5 and 106.2%. The recovery rates on the 15th day were 88.0-102.2%.

From the 3rd day to the 15th day after the ozonated saline was prepared, chlorate was detected in the blood bag subgroup ([Fig. 2A](#f2-etm-0-0-9005){ref-type="fig"} and [B](#f2-etm-0-0-9005){ref-type="fig"}) and the saline bottle subgroup ([Fig. 2C](#f2-etm-0-0-9005){ref-type="fig"} and [D](#f2-etm-0-0-9005){ref-type="fig"}). As time increased, the chlorate content in the two subgroups increased. There was no significant difference in the chlorate content between the 3rd and the 6th day in the blood bag and the saline bottle subgroups. However, on the 15th day, the chlorate content in the ozone-saline blood bag subgroup was significantly increased at all ozone concentrations compared with the corresponding levels on the 3rd and 6th days ([Fig. 2B](#f2-etm-0-0-9005){ref-type="fig"}). In the saline bottle subgroup, the chlorate content on the 15th day was only significantly increased compared with that on the 3rd and 6th day in the same group (20 µg/ml ozone). No significance was observed for the 0, 40 and 60 µg/ml ozone groups across the time-points examined ([Fig. 2D](#f2-etm-0-0-9005){ref-type="fig"}).

On the 3rd, 6 and 15th day, for the blood bag subgroup ([Fig. 2B](#f2-etm-0-0-9005){ref-type="fig"}) and the saline bottle subgroup ([Fig. 2D](#f2-etm-0-0-9005){ref-type="fig"}) at the same time-points, the chlorate concentration increased with increasing concentrations of ozone.

Under the same conditions (at the same time-points and the same ozone concentration), in the ozone-resistant blood bag subgroup, the chlorate content in the ozonated saline was significantly lower than that in the saline bottle subgroup ([Fig. 3](#f3-etm-0-0-9005){ref-type="fig"}).

### Perchlorate was not detected in the ozone-saline or oxygen-saline solution

The Five standard solutions with different concentrations (1, 2, 5, 10 and 20 µg/l) were added from low to high concentration for the spiked recovery test. The recovery rates were 86.6-101.0% on the 3rd day, 89.4-105.0% on the 6th day and 83.6-102.0% on the 15th day. The mass spectrometry results indicated that perchlorate was not detected on the 3rd, 6 and 15th day in either the ozone-saline or oxygen-saline solutions.

Discussion
==========

The results of the present study indicated that ozone is able to oxidize chloride ions in saline to form chlorate and the chlorate content gradually increased with time. In addition, higher ozone concentrations result in increased chlorate levels. Importantly, ozone may react with its container and thereby increase the levels of toxic substances in the ozone solution.

In the present study, when 100 ml of 20-60 µg/ml ozone was mixed with an equal volume of saline, the content of chlorate in the ozonated saline was between 0.90±0.14 and 207.6±15.63 µg/l. A low level (\<0.4 µg/l) of chlorate was detected in the absence of ozone in the blood bag, this could be a result of detection errors of the machine, or from the material of the blood bag. To the best of our knowledge, no study has reported the toxic dose of intravenously infused chlorate, although the World Health Organization Guidelines for drinking-water quality stipulated that the maximum permitted concentration of chlorate in drinking water is 0.7 mg/l ([@b43-etm-0-0-9005]). One study observed the effect of intravenous or oral sodium chlorate administration on the fecal shedding of *Escherichia coli* in sheep. Sodium chlorate (150 mg/kg) was infused over 3 h or less (a volume of 0.9% physiological saline containing 150 mg/kg sodium chlorate in a total volume of 250 ml), whilst the control group was administered the same dose of sodium chlorate orally. The content of NaClO~3~ in the serum of sheep was measured at 4, 8, 16, 24 and 36 h after administration. The highest concentration of NaClO~3~ in the serum was observed at 4 h of infusion (194.1±28.4 µg/l). The same dose (150 mg/kg NaClO~3~) was given orally, which also indicated a peak serum level after 4 h, reaching 138.9±13.2 µg/l ([@b44-etm-0-0-9005]). According to the results of the present study, the chlorate content in 100 ml ozonized saline was between 0.90±0.14 µg/l and 207.6±15.63 µg/l; this was much lower than the aforementioned toxic dose of chlorate and the maximum limit of the drinking-water standard setting after metabolism in the serum. However, since the chlorate in the ozone-saline solution is administered intravenously, its toxicity requires careful re-evaluation.

On the 3rd, 6 and 15th day, no chlorite was detected in any of the groups. It is speculated that the ozonated saline did not form any chlorite or the chlorite that had been formed within 3 days continued to be oxidized by ozone, turning into chlorate. On the 3rd, 6 and 15th day, no perchlorate was detected in the two groups. It appears that ozone mixed with normal saline does not produce perchlorate within the observed timeframe (15 days) in the present study. Since hypochlorite is formed instantaneously and decomposes rapidly, no hypochlorite was detected in the present study.

In order to simulate the ozone and saline reaction scenarios in the clinic, the present study used two ozone-saline containers that are commonly used in clinical settings: Saline bottles (polypropylene) and ozone-resistant blood transfusion bags \[medical polyvinyl chloride, di(2-ethyl) hexyl phthalate plasticized\]. The results suggested that under the same conditions, the chlorate content in ozonated saline in the blood bag made of ozone-resistant material was much lower than that in the saline bottle. As the reaction time went on, the chlorate content increased significantly. It may therefore be indicated that the material of the infusion container is able to affect the content of the toxic substances in the solution. The saline bottle material (polypropylene) may be oxidized by ozone, resulting in an increase of the chlorate content. These results suggested that the syringe and reaction container used for ozone therapy should consist of ozone-resistant materials, which would be effective in reducing the production of chlorate or any other toxic substances.

Previous studies indicated that oral administration of chlorate has multiple toxic effects. Ali *et al* ([@b45-etm-0-0-9005]) reported that a single oral dose of 100-750 mg/kg sodium chlorate in rats caused intestinal DNA damage through the production of ROS. Another study from the same group suggested that the same dose of sodium chlorate caused acute kidney injury in rats by producing an imbalance of redox reactions ([@b46-etm-0-0-9005]). Furthermore, different doses of sodium chlorate (0.106-1.06 mg/ml) not only induced oxidative stress in human red blood cells *in vitro*, leading to extensive damage to the cell membrane and reducing the anti-oxidant response, but also changed the morphology of red blood cells, increasing osmotic fragility. At the same time, exposure to different concentrations of sodium chlorate (0-10 nM) may lead to dose-dependent hemolysis ([@b47-etm-0-0-9005]). Chlorate and perchlorate affect the function of the thyroid gland. Following short-term (7 days) exposure to perchlorate (10 mg/l) and chlorate (100 mg/l) in rats, serum T4 was significantly lower than that in the control group ([@b48-etm-0-0-9005]). The incidence of thyroid follicular cell hypertrophy in male and female rats administered sodium chlorate was higher and the incidence of thyroid cancer was higher in the 2,000 mg/l chlorate group compared with that in the control group; furthermore, a small amount of islet cell tumors were produced in female rats exposed to sodium chlorate ([@b49-etm-0-0-9005]). As intravenous infusion therapy with ozonated saline usually requires repeated administrations in the short-term, further basic and clinical research is required to determine whether the accumulation of chlorate is able to affect blood, kidney and thyroid function.

According to Bocci *et al* ([@b41-etm-0-0-9005]), intravenous infusion of ozonated saline is potentially toxic and therefore, they do not support the systemic administration of ozone in this way. The specific reasons are as follows: i) Ozonated saline may contain toxic substances including H~2~O~2~, hypochlorous and hypochlorous acid; ii) ozonation of saline is an unstable process and if it is not injected on time, O~3~ will completely decompose within 60 min; iii) during the infusion, the blood flow rate in the vein affects the concentration of H~2~O~2~-O~3~, suggesting that there may be a variable biological oxidation process. Therefore, the therapy does not meet the therapeutic principles of clinical drugs, namely stability and clearly defined active components ([@b41-etm-0-0-9005]).

The present study suggests that there may be toxic substances, e.g. chlorate, in ozonated saline, and the toxic dose of these substances in the human body remains to be determined. As such, the outcome of long-term intravenous infusion of ozonized saline remains uncertain.

Of note, the present study has several limitations. The content of chlorite, chlorate and perchlorate in ozonated saline was only measured after 3 days in the present study, and it remains elusive whether any chlorite was present in the ozonated saline at earlier stages. In the clinic, ozonated saline is prepared upon its use. In addition, chlorate and perchlorate are relatively stable; therefore, their concentrations in the first 3 days should be less than that detected on the third day. As such, the current data are instructive for clinical work. Usually, 100 ml of ozonated saline is infused within half an hour during clinical treatment. Bocci *et al* ([@b41-etm-0-0-9005]) reported that ozone totally decomposed within 60 min and that intravenous infusion of ozone solutions should be completed within one hour; therefore, detection of chlorite, chlorate and perchlorate in ozonated saline as soon as possible would provide results that are more representative of the clinical scenario. However, in the present study, differences between 3, 6 and 15 days observed indicate that there may have still been some ozone present, that may have led to the generation of chlorate beyond several days.

In conclusion, ozonated saline solution contains chlorate and the ozone may react with the polypropylene of the saline bottle to increase the chlorate content in the solution. Although studies have reported that intravenous infusion of ozonated saline is safe and effective, due to the lack of blood chlorate toxicology studies, it remains elusive whether the levels of chlorate detected in the ozonated saline in this present study (0.90±0.14-207.6±15.63 µg/l) are safe for the solution to be given intravenously. Therefore, clinical intravenous infusion of ozonated saline should be used with caution. Importantly, ozone reacts with various containers and an ozone-resistant container for ozonated solution infusion is recommended.
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![Materials used for the preparation of ozonated saline. IC-MS was used to detect chlorite, chlorate and perchlorate. (A) Ozone-resistant 50-ml syringes were used to inject varying concentrations of ozone and saline; (B) saline bottles that were used as the container for the ozone and saline solutions in the saline bottle subgroup; (C) ozone-resistant blood bags that were used to hold the ozone and saline solutions in the blood bag subgroup. (D) IC-MS results of 5 µg/l chlorite, chlorate and perchlorate standards. The retention times of 7.2, 13.5 and 20.8 min corresponded to chlorite, chlorate and perchlorate, respectively. IC-MS, ion chromatography-mass spectrometry; cps, counts per second.](etm-20-03-2569-g00){#f1-etm-0-0-9005}

![Changes in the chlorate content in ozonated saline on the 3rd, 6 and 15th day. By using IC-MS, the chlorate content was detected on the 3rd, 6 and 15th day in (A and B) the blood bag and (C and D) saline bottle subgroups. The chlorate concentration appeared to increase with time. (A) IC-MS detected chlorate in 40 µg/ml ozonated saline in the blood bag subgroup (peak time, 13.5 min; intensity, 210 cps) on the 3rd day. (B) Chlorate content in the blood bag subgroup with varying concentrations of ozonated saline on the 3rd, 6 and 15th day after mixing. There was no statistically significant difference in the chlorate content between the 3rd day and the 6th day after treating with any concentration of ozone. On the 15th day, the chlorate content increased significantly compared with that on the 3rd and 6th days in all treatment groups. (C) Chlorate was detected by IC-MS on the 3rd day in 40 µg/ml ozonated saline in the saline bottle subgroup (peak time, 13.5 min; intensity, 3,805 cps). (D) Chlorate content in the saline bottle subgroup with varying concentrations of ozonated saline on the 3rd, 6 and 15th day after mixing. On the 15th day, the chlorate content increased significantly compared with that on the 3rd day and the 6th day in the 20 µg/ml ozone-saline solution. There was no significant difference between the 3rd day, the 6th day and the 15th day in the 40 and 60 µg/ml ozone-saline solution. However, the chlorate content in ozonated saline was elevated with the increase of the ozone concentration. Values are expressed as the mean ± standard deviation (n=3 for each group). Statistical analyses were performed by repeated-measures two-way analysis of variance, followed by Tukey\'s multiple-comparisons tests. ^\*\*\*^P\<0.001 compared with the 3rd day and the 6th day; ^\#^P\<0.05, ^\#\#\#^P\<0.001. IC-MS, ion chromatography-mass spectrometry; cps, counts per second.](etm-20-03-2569-g01){#f2-etm-0-0-9005}

![Reaction containers affected the chlorate content in the ozonated saline group. The chlorate content was detected using ion chromatography-mass spectrometry. The chlorate content of the ozonated saline in the ozone-resistant blood bag subgroup was significantly lower than that in the saline bottle subgroup at the same time-point with the same ozone concentration. ^\*\*\*^P\<0.001 compared with the blood bag group at the same time-point and with the same ozone concentration. Values are expressed as the mean ± standard deviation (n=3 for each group). Statistical analyses consisted of repeated-measures two-way analysis of variance tests, followed by Sidak\'s multiple-comparisons tests.](etm-20-03-2569-g02){#f3-etm-0-0-9005}

###### 

Comparisons of OAH and ozonated saline infusion.

  Treatment                  Blood drawing and transfusion                       OD of puncture needle   Infusion environment       Operational difficulty   Patient acceptance   Treatment duration   Cost              Dispute in the medical field^[a](#tfn1-etm-0-0-9005){ref-type="table-fn"}^
  -------------------------- --------------------------------------------------- ----------------------- -------------------------- ------------------------ -------------------- -------------------- ----------------- ----------------------------------------------------------------------------
  OAH                        Yes^[b](#tfn2-etm-0-0-9005){ref-type="table-fn"}^   20 G                    Clean area for operation   High                     Difficult            Relatively long      Relatively high   No
  Ozonated saline infusion   No                                                  24 G                    Low requirement            Low                      Easy                 Relatively short     Relatively low    Yes

^a^Bocci *et al*, J Pharm Pharmacol 64(4): 482-489, 2012.

^b^Hu *et al*, J Pain Res 11: 1637-1643, 2018. OD, outer diameter; OAH, ozonated autohemotherapy.

###### 

Mass spectrometry conditions.

  Analyte       Detected ion pairs (m/z)   DP (V)   CE (V)
  ------------- -------------------------- -------- --------
  Chlorite      66.9/50.8                  -80      -20
  Chlorate      82.9/66.9                  -50      -30
  Perchlorate   98.9/82.9                  -60      -30

m/z, ratio of mass to charge; DP, declustering potential; CE, collision energy.
